image
Basic Materials - Agricultural Inputs - NASDAQ - US
$ 5.1528
0.838 %
$ 7.03 M
Market Cap
-0.76
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jan, 30, 2025.

The intrinsic value of one RKDA stock under the worst case scenario is HIDDEN Compared to the current market price of 5.15 USD, Arcadia Biosciences, Inc. is HIDDEN

This DCF valuation model was last updated on Jan, 30, 2025.

The intrinsic value of one RKDA stock under the base case scenario is HIDDEN Compared to the current market price of 5.15 USD, Arcadia Biosciences, Inc. is HIDDEN

This DCF valuation model was last updated on Jan, 30, 2025.

The intrinsic value of one RKDA stock under the best case scenario is HIDDEN Compared to the current market price of 5.15 USD, Arcadia Biosciences, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS
FINANCIALS
5.33 M REVENUE
-46.46%
-13.9 M OPERATING INCOME
28.17%
-14 M NET INCOME
10.42%
-15.3 M OPERATING CASH FLOW
-9.42%
-4.34 M INVESTING CASH FLOW
-306.56%
5.51 M FINANCING CASH FLOW
21.97%
1.54 M REVENUE
17.69%
-1.76 M OPERATING INCOME
-88.89%
-2.4 M NET INCOME
-226.30%
-1.75 M OPERATING CASH FLOW
28.66%
180 K INVESTING CASH FLOW
-96.12%
4 K FINANCING CASH FLOW
0.00%
Balance Sheet Arcadia Biosciences, Inc.
image
Current Assets 15 M
Cash & Short-Term Investments 11.6 M
Receivables 514 K
Other Current Assets 2.82 M
Non-Current Assets 4.73 M
Long-Term Investments 0
PP&E 1.18 M
Other Non-Current Assets 3.56 M
Current Liabilities 3.59 M
Accounts Payable 801 K
Short-Term Debt 852 K
Other Current Liabilities 1.94 M
Non-Current Liabilities 3.41 M
Long-Term Debt 155 K
Other Non-Current Liabilities 3.26 M
EFFICIENCY
Earnings Waterfall Arcadia Biosciences, Inc.
image
Revenue 5.33 M
Cost Of Revenue 3.3 M
Gross Profit 2.03 M
Operating Expenses 15.9 M
Operating Income -13.9 M
Other Expenses 48 K
Net Income -14 M
RATIOS
38.09% GROSS MARGIN
38.09%
-261.50% OPERATING MARGIN
-261.50%
-262.31% NET MARGIN
-262.31%
-108.88% ROE
-108.88%
-70.95% ROA
-70.95%
-82.20% ROIC
-82.20%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Arcadia Biosciences, Inc.
image
Net Income -14 M
Depreciation & Amortization 984 K
Capital Expenditures -5 K
Stock-Based Compensation 717 K
Change in Working Capital -3.51 M
Others -3.12 M
Free Cash Flow -15.3 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Arcadia Biosciences, Inc.
image
Wall Street analysts predict an average 1-year price target for RKDA of $6 , with forecasts ranging from a low of $6 to a high of $6 .
RKDA Lowest Price Target Wall Street Target
6 USD 16.44%
RKDA Average Price Target Wall Street Target
6 USD 16.44%
RKDA Highest Price Target Wall Street Target
6 USD 16.44%
4. DIVIDEND ANALYSIS
5. COMPETITION
6. Ownership
Insider Ownership Arcadia Biosciences, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
2.88 K USD 2
3-6 MONTHS
0 USD 0
6-9 MONTHS
1.44 K USD 1
9-12 MONTHS
Date Value Insider Amount Avg Price
6 months ago
Aug 01, 2024
Bought 1.44 K USD
Kawakami Mark
Chief Financial Officer
+ 700
2.06 USD
6 months ago
Aug 01, 2024
Bought 1.44 K USD
Schaefer Thomas J.
Chief Executive Officer
+ 700
2.06 USD
1 year ago
Feb 01, 2024
Bought 1.44 K USD
Schaefer Thomas J.
Chief Financial Officer
+ 700
2.06 USD
1 year ago
Aug 04, 2023
Bought 2.38 K USD
Schaefer Thomas J.
Chief Financial Officer
+ 649
3.67 USD
1 year ago
May 30, 2023
Bought 21.5 K USD
Jacot Stanley Jr
Chief Executive Officer
+ 5000
4.31 USD
2 years ago
Feb 01, 2023
Bought 161 USD
Schaefer Thomas J.
Chief Financial Officer
+ 700
0.23 USD
2 years ago
Aug 01, 2022
Bought 490 USD
Haley Pamela
Chief Financial Officer
+ 700
0.7 USD
4 years ago
Aug 03, 2020
Bought 1.85 K USD
Plavan Matthew T
Chief Executive Officer
+ 585
3.16 USD
4 years ago
Aug 03, 2020
Bought 2.21 K USD
Shultz Randall
Chief Technology Officer
+ 700
3.16 USD
4 years ago
Aug 03, 2020
Bought 2.21 K USD
Haley Pamela
Chief Financial Officer
+ 700
3.16 USD
4 years ago
Feb 03, 2020
Bought 1.2 K USD
Haley Pamela
Chief Financial Officer
+ 700
1.72 USD
4 years ago
Feb 03, 2020
Bought 1.2 K USD
Reiter Sarah
Chief Commercial Officer
+ 700
1.72 USD
4 years ago
Feb 03, 2020
Bought 1.2 K USD
Plavan Matthew T
Chief Executive Officer
+ 700
1.72 USD
5 years ago
Dec 23, 2019
Bought 5.36 K USD
Reiter Sarah
Chief Commercial Officer
+ 900
5.95 USD
5 years ago
Nov 19, 2019
Bought 4.52 K USD
Reiter Sarah
Chief Commercial Officer
+ 1000
4.52 USD
5 years ago
Nov 18, 2019
Bought 21.2 K USD
Murray Lilian Shackelford
Director
+ 5000
4.25 USD
5 years ago
Nov 14, 2019
Bought 4.08 K USD
Plavan Matthew T
Chief Executive Officer
+ 1000
4.0795 USD
5 years ago
Sep 23, 2019
Bought 10.5 K USD
Plavan Matthew T
Chief Executive Officer
+ 2000
5.25 USD
5 years ago
Sep 17, 2019
Bought 29.4 K USD
Comcowich Kevin
Director
+ 5000
5.8776 USD
5 years ago
Sep 10, 2019
Bought 6.52 K USD
Plavan Matthew T
Chief Executive Officer
+ 1000
6.5205 USD
5 years ago
Sep 10, 2019
Bought 6.49 K USD
Plavan Matthew T
Chief Executive Officer
+ 1000
6.493 USD
5 years ago
Sep 10, 2019
Bought 7.78 K USD
Reiter Sarah
Chief Commercial Officer
+ 1200
6.48 USD
5 years ago
Sep 10, 2019
Bought 64.9 K USD
Comcowich Kevin
Director
+ 10000
6.49 USD
5 years ago
Sep 10, 2019
Bought 32.4 K USD
Comcowich Kevin
Director
+ 5000
6.4866 USD
5 years ago
Aug 28, 2019
Bought 6.88 K USD
Plavan Matthew T
Chief Financial Officer
+ 1000
6.88 USD
5 years ago
Aug 27, 2019
Bought 17.9 K USD
Plavan Matthew T
Chief Financial Officer
+ 2000
8.93 USD
5 years ago
Aug 27, 2019
Bought 8.95 K USD
Plavan Matthew T
Chief Financial Officer
+ 1000
8.95 USD
5 years ago
Aug 27, 2019
Bought 9.3 K USD
Plavan Matthew T
Chief Financial Officer
+ 1000
9.3 USD
5 years ago
Aug 27, 2019
Bought 9.32 K USD
Plavan Matthew T
Chief Financial Officer
+ 1000
9.32 USD
5 years ago
Aug 26, 2019
Bought 9.22 K USD
Plavan Matthew T
Chief Financial Officer
+ 1000
9.22 USD
5 years ago
Aug 26, 2019
Bought 8.33 K USD
Plavan Matthew T
Chief Financial Officer
+ 1000
8.33 USD
6 years ago
Mar 23, 2018
Sell 167 K USD
Rey Eric J.
Director
- 5000
33.44 USD
6 years ago
Mar 23, 2018
Sell 57.3 K USD
Lu Zhongjin
VP Product Development
- 1750
32.74 USD
6 years ago
Mar 14, 2018
Sell 950 K USD
Rey Eric J.
Director
- 21005
45.209 USD
6 years ago
Mar 15, 2018
Sell 15 K USD
Rey Eric J.
Director
- 250
60 USD
7 years ago
Nov 17, 2017
Sell 1.36 K USD
Lu Zhongjin
VP Product Development
- 5950
0.228 USD
7 years ago
Jun 08, 2017
Bought 3.75 K USD
Rey Eric J.
Director
+ 5000
0.75 USD
8 years ago
Aug 04, 2016
Sell 251 USD
Salameh Roger
Chief Operating Officer
- 100
2.51 USD
8 years ago
Jun 13, 2016
Sell 20.6 K USD
Brandwein Steven F.
Interim Chief Financ. Officer
- 8280
2.4934 USD
8 years ago
Apr 25, 2016
Sell 4.17 K USD
Brandwein Steven F.
Interim Chief Financ. Officer
- 1720
2.424 USD
8 years ago
Apr 04, 2016
Sell 3.57 K USD
Knauf Vic C.
Chief Scientific Officer
- 1200
2.975 USD
8 years ago
Apr 05, 2016
Sell 4.93 K USD
Knauf Vic C.
Chief Scientific Officer
- 1653
2.982 USD
8 years ago
Mar 03, 2016
Sell 891 USD
Knauf Vic C.
Chief Scientific Officer
- 300
2.97 USD
8 years ago
Mar 04, 2016
Sell 9.58 K USD
Knauf Vic C.
Chief Scientific Officer
- 2973
3.224 USD
9 years ago
Feb 01, 2016
Sell 5 K USD
Knauf Vic C.
Chief Scientific Officer
- 1666
3.003 USD
9 years ago
Feb 01, 2016
Sell 8.79 K USD
Rey Eric J.
President and CEO
- 3000
2.9313 USD
9 years ago
Feb 03, 2016
Sell 556 USD
Rey Eric J.
President and CEO
- 200
2.78 USD
9 years ago
Dec 15, 2015
Sell 35.8 K USD
Brandwein Steven F.
Interim Chief Financ. Officer
- 10035
3.5663 USD
9 years ago
Dec 01, 2015
Sell 24.5 K USD
Knauf Vic C.
Chief Scientific Officer
- 6300
3.8889 USD
9 years ago
Dec 02, 2015
Sell 35.6 K USD
Knauf Vic C.
Chief Scientific Officer
- 8700
4.0959 USD
9 years ago
Nov 11, 2015
Sell 13.2 K USD
Knauf Vic C.
Chief Scientific Officer
- 4527
2.9138 USD
9 years ago
Oct 09, 2015
Sell 15.5 K USD
Rey Eric J.
President and CEO
- 5145
3.0066 USD
9 years ago
Oct 08, 2015
Sell 4.48 K USD
Rey Eric J.
President and CEO
- 1500
2.988 USD
9 years ago
Oct 07, 2015
Sell 10.5 K USD
Rey Eric J.
President and CEO
- 3500
3.0025 USD
9 years ago
Oct 06, 2015
Sell 13.4 K USD
Rey Eric J.
President and CEO
- 4100
3.2803 USD
9 years ago
Oct 05, 2015
Sell 44.5 K USD
Rey Eric J.
President and CEO
- 14136
3.1509 USD
9 years ago
Oct 02, 2015
Sell 8.66 K USD
Rey Eric J.
President and CEO
- 2900
2.9874 USD
9 years ago
Oct 01, 2015
Sell 13.2 K USD
Rey Eric J.
President and CEO
- 4600
2.8722 USD
9 years ago
Sep 30, 2015
Sell 18.4 K USD
Rey Eric J.
President and CEO
- 5800
3.1697 USD
9 years ago
Sep 29, 2015
Sell 13.7 K USD
Rey Eric J.
President and CEO
- 3900
3.5173 USD
9 years ago
Sep 28, 2015
Sell 22.8 K USD
Rey Eric J.
President and CEO
- 6200
3.6854 USD
9 years ago
Sep 25, 2015
Sell 40.3 K USD
Rey Eric J.
President and CEO
- 10000
4.027 USD
9 years ago
Sep 24, 2015
Sell 30.7 K USD
Rey Eric J.
President and CEO
- 7089
4.3239 USD
9 years ago
Sep 23, 2015
Sell 19.2 K USD
Rey Eric J.
President and CEO
- 4000
4.8022 USD
9 years ago
Sep 14, 2015
Sell 3.31 K USD
Emlay Don
VP Regulatory and Compliance
- 689
4.8061 USD
9 years ago
Sep 11, 2015
Sell 11.2 K USD
Emlay Don
VP Regulatory and Compliance
- 2284
4.9181 USD
9 years ago
Sep 10, 2015
Sell 2.89 K USD
Emlay Don
VP Regulatory and Compliance
- 548
5.2708 USD
9 years ago
Sep 11, 2015
Sell 8.11 K USD
Salameh Roger
VP Business Development
- 1648
4.9181 USD
9 years ago
Sep 11, 2015
Sell 5.25 K USD
Lu Zhongjin
VP Product Development
- 1068
4.9181 USD
9 years ago
Sep 10, 2015
Sell 8.3 K USD
Salameh Roger
VP Business Development
- 1575
5.2708 USD
9 years ago
Sep 09, 2015
Sell 15.3 K USD
Salameh Roger
VP Business Development
- 2765
5.5458 USD
9 years ago
Sep 08, 2015
Sell 19.3 K USD
Salameh Roger
VP Business Development
- 3500
5.5089 USD
9 years ago
Sep 10, 2015
Sell 6.86 K USD
Lu Zhongjin
VP Product Development
- 1302
5.2708 USD
9 years ago
Sep 09, 2015
Sell 13.1 K USD
Lu Zhongjin
VP Product Development
- 2370
5.5458 USD
9 years ago
Sep 08, 2015
Sell 16.5 K USD
Lu Zhongjin
VP Product Development
- 3000
5.5089 USD
9 years ago
Sep 10, 2015
Sell 3.03 K USD
Knauf Vic C.
Chief Scientific Officer
- 575
5.2708 USD
9 years ago
Sep 09, 2015
Sell 15.3 K USD
Knauf Vic C.
Chief Scientific Officer
- 2765
5.5458 USD
9 years ago
Sep 08, 2015
Sell 19.3 K USD
Knauf Vic C.
Chief Scientific Officer
- 3500
5.5089 USD
9 years ago
May 20, 2015
Bought 3 M USD
Garg Uday
director, 10 percent owner:
+ 375000
8 USD
9 years ago
May 20, 2015
Bought 3 M USD
Mandala Agribusiness Co-Investments I Ltd
10 percent owner
+ 375000
8 USD
9 years ago
May 20, 2015
Bought 3 M USD
Mandala Agribusiness Co-Investments I Ltd
10 percent owner
+ 375000
8 USD
9 years ago
May 20, 2015
Bought 3 M USD
Garg Uday
director, 10 percent owner:
+ 375000
8 USD
9 years ago
May 20, 2015
Bought 8 M USD
Shupp Darby E
director, 10 percent owner:
+ 1000000
8 USD
9 years ago
May 20, 2015
Bought 100 K USD
Reis James Richard
Director
+ 12500
8 USD
9 years ago
May 20, 2015
Bought 8 M USD
BISHOP TERRI C
10 percent owner
+ 1000000
8 USD
7. News
ARCADIA BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Arcadia Biosciences, Inc. - RKDA NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Arcadia Biosciences, Inc. (NasdaqCM: RKDA) and Roosevelt Resources LP. Pursuant to the terms of the agreement, upon completion of the Merger, Arcadia stockholders are expected to own approximately 10% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are a. businesswire.com - 1 month ago
Arcadia Biosciences to Merge With Roosevelt, Shares Surge 105% RKDA inks deal with Roosevelt to become a new entity, Roosevelt Resources, with Roosevelt as the majority shareholder. zacks.com - 1 month ago
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Arcadia Biosciences, Inc. - RKDA NEW YORK , Dec. 6, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm by ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Arcadia Biosciences, Inc. (NASDAQ: RKDA ), relating to the proposed merger with Roosevelt Resources LP. prnewswire.com - 1 month ago
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Arcadia Biosciences, Inc. NEW YORK , Dec. 6, 2024 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Arcadia Biosciences, Inc. (NASDAQ: RKDA) and its board of directors concerning the proposed acquisition of the company by Roosevelt Resources LP. Arcadia stockholders will own approximately 10% of the combined company. prnewswire.com - 1 month ago
Shareholder Alert: Ademi LLP investigates whether Arcadia Biosciences, Inc. is obtaining a Fair Price for its Public Shareholders MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating Arcadia (NASDAQ: RKDA) for possible breaches of fiduciary duty and other violations of law in its transaction with Roosevelt Resources. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. Following the closing of the transaction, the current equity owners of Roosevelt Resources and the Arcadia shareholders. businesswire.com - 1 month ago
RKDA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Arcadia Biosciences, Inc. Is Fair to Shareholders NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Arcadia Biosciences, Inc. (NASDAQ: RKDA) and Roosevelt Resources LP is fair to Arcadia shareholders. Upon closing of the proposed transaction, Arcadia shareholders are expected to own approximately 10% of the combined company. Halper Sadeh encourages Arcadia shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212. businesswire.com - 1 month ago
Arcadia Biosciences (RKDA) Enters Into Business Combination Agreement with Roosevelt Resources in All-Stock Transaction DALLAS--(BUSINESS WIRE)--Arcadia Biosciences, Inc.® (Nasdaq: RKDA) and Roosevelt Resources LP announced today that they have entered into a definitive securities exchange agreement which, when completed, will combine the two companies in an all-stock transaction. Under the terms of the agreement, Arcadia will issue to the partners of Roosevelt shares of Arcadia common stock at the closing of the transaction in exchange for all of the equity interests in Roosevelt. Following the closing of the t. businesswire.com - 1 month ago
Arcadia Biosciences' Q3 Earnings Miss Estimates, Sales Increase Y/Y RKDA witnesses a solid 55% improvement in Zola sales in Q3. The company continues to invest to grow the Zola brand. zacks.com - 2 months ago
Arcadia Biosciences (RKDA) Reports Q3 Loss, Tops Revenue Estimates Arcadia Biosciences (RKDA) came out with a quarterly loss of $0.87 per share versus the Zacks Consensus Estimate of a loss of $0.77. This compares to loss of $1.83 per share a year ago. zacks.com - 2 months ago
Arcadia Biosciences, Inc. (RKDA) Q3 2024 Earnings Call Transcript Arcadia Biosciences, Inc. (NASDAQ:RKDA ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Mark Kawakami - Chief Financial Officer T.J. Schaefer - President & Chief Executive Officer Conference Call Participants Ben Klieve - Lake Street Capital Markets Operator Good afternoon, and welcome to Arcadia Biosciences Third Quarter 2024 Financial Results and Business Highlights Conference Call. seekingalpha.com - 2 months ago
Arcadia Biosciences (RKDA) Announces Date of Third Quarter 2024 Financial Results and Business Highlights Conference Call DALLAS--(BUSINESS WIRE)--Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer and marketer of innovative, plant-based health and wellness products, today announced that it will release its financial and business results for the third quarter of 2024 after market close on November 12, 2024. The company has scheduled a conference call for 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss third-quarter results and key strategic achievements. Interested participants can join the conferenc. businesswire.com - 3 months ago
4 Agriculture - Products Stocks to Watch Despite Industry Concerns The near-term outlook for the Zacks Agriculture - Products industry is uncertain due to low commodity prices and inflated costs. Investors should watch BG, WFG, HYFM and RKDA, which are braving the industry headwinds. zacks.com - 3 months ago
8. Profile Summary

Arcadia Biosciences, Inc. RKDA

image
COUNTRY US
INDUSTRY Agricultural Inputs
MARKET CAP $ 7.03 M
Dividend Yield 0.00%
Description Arcadia Biosciences, Inc. produces and markets plant-based health and wellness products in the United States. It engages in developing crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients, health and wellness products, and their viability for industrial applications. The company was incorporated in 2002 and is headquartered in Davis, California.
Contact 202 Cousteau Place, Davis, CA, 95618 https://www.arcadiabio.com
IPO Date May 15, 2015
Employees 21
Officers Mr. Mark Kawakami Chief Financial Officer Mr. Thomas J. Schaefer C.F.A. Chief Executive Officer, President & Director